Derm Cases · Dermatology / Haematology / Hepatology
OSCE — Meltzer triad and cold-precipitating immunoglobulins: manage cryoglobulinaemic disease
An 8-minute OSCE station on Brouet typing of cryoglobulins, recognising mixed cryoglobulinaemic vasculitis (purpura–arthralgia–weakness, low C4, HCV link), Type I hyperviscosity red flags, correct sample handling, and rituximab/antiviral/plasma-exchange decisions.
On this page
Study tools
Target exams
Brief (to candidate)
A 58-year-old with chronic hepatitis C develops recurrent lower-limb palpable purpura, arthralgia and fatigue. Complements show very low C4 with near-normal C3. RF is positive. A second card describes a patient with Waldenström macroglobulinaemia, headache and blurred vision in the cold. You have 8 minutes to classify cryoglobulinaemia, plan correct laboratory handling, and escalate therapy for vasculitis vs hyperviscosity.
[7]Candidate instructions
- Explain the Brouet Type I / II / III classification.
- Recognise Meltzer's triad and the low C4 pattern in mixed disease.
- Link HCV (and other causes) and list required screens.
- Describe pre-analytical sample handling for cryoglobulin assay.
- Outline therapy: antiviral, rituximab, steroids, plasma exchange by severity/type.
Examiner checklist (mark each domain / 10)
| Domain | Key actions expected |
|---|---|
| Definition | Immunoglobulins that precipitate in the cold and redissolve on rewarming; clinical disease from hyperviscosity/precipitation (Type I) or immune-complex vasculitis (mixed)[1] |
| Brouet types | I: monoclonal Ig (MGUS/myeloma/WM) — hyperviscosity/thrombosis more than classic vasculitis. II: monoclonal IgM RF + polyclonal IgG (mixed). III: polyclonal mixed. Mixed disease → small-vessel vasculitis[1][2] |
| Mixed clinical | Meltzer triad: palpable purpura, arthralgia, weakness; often very low C4, RF+, HCV association; may involve nerves and kidneys |
| Lab handling | Blood drawn and transported warm (37°C) to lab; improper cooling causes false negatives — state this explicitly |
| Cause screen | HCV (and HBV/HIV as indicated), autoimmune disease, lymphoproliferative disease/SPEP-immunofixation for Type I |
| Therapy | Treat underlying cause (DAA for HCV when appropriate); rituximab cornerstone for mixed cryoglobulinaemic vasculitis; steroids for flares; plasma exchange for severe organ-threatening disease, hyperviscosity, or critical ischaemia; haematology for Type I clone-directed therapy[5][6] |
| Safety | Cold avoidance counselling; urgent PE pathway for hyperviscosity/RPGN/severe neuropathy |
Model key actions
- Classify Type I vs mixed and recognise purpura–arthralgia–weakness + low C4 as mixed cryoglobulinaemia.[1]
- Always warm-handle cryoglobulin samples; screen HCV and paraprotein.[2]
- Use rituximab ± PE for severe mixed vasculitis; treat the clone or virus driving production.[6]
Common errors
- Sending cryoglobulin sample on ice/room-temp incorrectly.
- Missing HCV testing in mixed disease.
- Treating Type I hyperviscosity as simple rash without haematology/PE.
- Ignoring renal/neurologic involvement.
- Using prolonged steroids alone without addressing B-cell/virus drivers.
References5ShowHide
- [1]Roccatello D, Saadoun D, Ramos-Casals M, et al. Cryoglobulinaemia. Nature Reviews Disease Primers, 2018.PMID 30072738
- [2]Retamozo S, Quartuccio L, Ramos-Casals M, et al. Cryoglobulinemia. Medicina Clinica, 2022.PMID 35216803
- [5]Desbois AC, Cacoub P, Saadoun D. Cryoglobulinemia: An update in 2019. Joint Bone Spine, 2019.PMID 30731128
- [6]Quartuccio L, Bortoluzzi A, Scirè CA, et al. Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC). Clinical Rheumatology, 2023.PMID 36169798
- [7]Saadoun D, Thibault V, Si Ahmed SN, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study Ann Rheum Dis, 2016.PMID 26567178